All the Active Ingredient Drugs
Antifungal, Triazole Derivatives. Fluconazole 50 mg / 5 ml. BOTTLE (pwdr. for oral susp.): 35ml. Dosage should be just. individ.
Fungal infec.:
Cryptococcal meningit.
Coccidioidomycos.
Invas. candidias.
Mucos. candidias. includ. oropharyng., oesophag. candidias., candiduria, chron. mucocutaneous candidias.
Chron. oral atrophic candidias. (denture sore mouth) if dent. hygiene or topic. tmt. are insuffic.
Vagin. candidias., acute/recurrent; when local ther. is not appropr..
Candidal balanitis when local ther. is not approp.
Dermatomycos. include. tinea pedis, tinea corporis, tinea cruris, tinea versicolor, derm. candida infec. when system. ther. is indicated.
Tinea unguinium (onychomycosis) when other agents are not consid. appropriate.
Fluconazole is indic. in adult. for the prophylaxis of:
Relapse of cryptococcal meningit. in pts. with high risk of recur.
Relapse of oropharyng./oesophag. candidiasis in pts. infec. with HIV
and with high risk of experienc. relapse.
To reduce the incidence of recur. vag. candid. (4 or more episodes a year). Prophylaxis of candidal infec. in pts. with prolong. neutropen. (such as pts. with haematolog. malignan. receiv. chemother. or pts. receiving Hematopoietic Stem Cell Transplant.
Term newborn infan., infant., toddlers, child., adolescen. aged from 0 - 17 yrs. old:
Tmt. of mucosal candidiasis (oropharyngeal, oesophageal), invas. candidiasis and cryptococcal meningit. and the prophylaxis of candidal infec. in immunocomprom. pts. Fluconazole can be used as mainten. ther. to prevent relapse of cryptococcal meningitis in child. with high risk of reoccurrence.
C/I: Hypersens. Coadmin. with of terfenadine in pts. receiv. fluconazole at multiple doses of 400 mg/d or higher based upon results of a multiple dose interact. study. Coadmin. of other med. products known to prolong the QT interv. and which are metabolised via the P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, erythromycin.
Antifungal. Fluconazole 50, 100, 150, 200 mg. CAPS: 1 x 150 mg, 7 x 50 mg, 100 mg,
200 mg,.
Dermatomycos. where top. ther.
inappropriate due to site, severity or
extent of infect., tinea ped., cruris,
candida infects: 150 mg 1 x wkly or 50
mg 1 x dly for 2-4 wks. Tinea ped. may
req. up to 6 wks. Tinea versicolor: 50 mg
1 x dly for 2-4 wks.
Dermatomycos. where top. ther.
inapprop. due to site, severity or extent
of infect. incl. tinea pedis, tinea cruris,
tinea versicolor and candida infects.
C/I: Hypersens. Coadmin. of terfenadine in pts. receiving fluconazole at multiple doses of 400 mg /d or higher. Coadmin. of med. prod. known to prolong QT interval and which are metabol. via the cytochr. P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine and erythromycin.
Antifungal. Fluconazole 150 mg. CAPS: 1. Tinea pedis, corperis, cruris,
candida infects: 150 mg 1 x wkly or 50
mg 1 x dly for 2-4 wks. See lit. Tinea
versicolor: 50 mg 1 x dly for 2-4 wks.
Elderly: See lit.
Cryptococcos., incl. cryptococ.
meningitis; maint. in AIDS pts., systemic
candidias., mucosal candidiasis., vag.
candidias., acute or recurrent,
dermatomycosis; candida infects. where
topic. ther. inapprop.
C/I: Hypersens., coadmin. with
terfenadine in pts. receiving fluconazole
at multiple doses of 400 mg dly or
higher, coadmin. with cisapride.
Antifungal. Fluconazole 2 mg/ml. VIAL (sol. for infus.): 1 x 50 ml. Adults:
Cryptococc. meningit: 400 mg on 1st
day, then 200-400 mg dly, single dly
dose; system. candidias: 200-400 mg
dly; mucosal candidias: 50 mg dly;
other mucosal candid. infects: 50-100
mg dly; vag. candidias: 150 mg single
dose. Elderly, child over 4 wks: As for
adults. Child under 4 wks., pts with
ren./hepat. dysfunct: See lit.
Cryptococc. infects., incl. cryptococc.
meningit., syst. candid., mucosal candid.
C/I: Hypersens. fluconazole, azoles. Not
to co-admin with drugs known to prolon
QT intervals/metabol. by CYP3A4. See lit.
Antifungal, Triazole Derivatives. Fluconazole 200 mg. HARD CAPS.:7. Dosage. should be ajust. individ.
Fungal infec.:
Cryptococcal meningit.
Coccidioidomycos.
Invas. candidias.
Mucos. candidias. includ. oropharyng., oesophag. candidias., candiduria,chron. mucocutaneous candidias.
Chron. oral atrophic candidias. (denture sore mouth) if dent. hygiene or topic. tmt. are insuffic.
Vagin. candidias., acute/ recurrent; when local ther. is not appropr..
Candidal balanitis when local ther. is not approp.
Dermatomycos. include. tinea pedis, tinea corporis, tinea cruris, tinea versicolor, derm. candida infec. when system. ther. is indicated.
Tinea unguinium (onychomycosis) when other agents are not consid. appropriate.
Fluconazole is indic. in adult. for the prophylaxis of:
Relapse of cryptococcal meningit. in pts. with high risk of recur.
Relapse of oropharyng./ oesophag. candidiasis in pts. infec. with HIV
Pts. with high risk of experienc. relapse.
To reduce the incidence of recur. vag. candid. (4 or more episodes a year).
Prophylaxis of candidal infec. in pts. with prolong. neutropen. (such as pts. with haematolog. malignan. receiv. chemother. or pts. receiving Hematopoietic Stem Cell Transplant.
Term newborn infan., infant., toddlers, child., adolescen. aged from 0 - 17 yrs. old:
tmt. of mucosal candidiasis (oropharyngeal, oesophageal), invas. candidiasis and cryptococcal meningit. and the prophylaxis of candidal infec. in immunocomprom. pts. Fluconazole can be used as mainten. ther. to prevent relapse of cryptococcal meningitis in child. with high risk of reoccurrence.
C/I: Hypersens. Coadmin. with of terfenadine in pts. receiv. fluconazole at multiple doses of 400 mg /d or higher based upon results of a multiple dose interact. study. Coadmin. of other med. products known to prolong the QT interv. and which are metabolised via the P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, erythromycin.
Antifungal. Fluconazole 2 mg/ml. VIAL ( Sol. for infus.): 1×50, 100, 200 ml.
Cryptococcosis: tmt. of cryptococc. meningitis. Load. dose: 400 mg×1/d on Day1.
Subseq. dose: 200 mg -400 mg/d, usually at least 6- 8 wks. In life threat. infect. dly. dose can be incr. to 800 mg. Maint. ther. to prevent relapse of cryptococcal mening. in pts. with high risk of recur.-200 mg×1/d, indefinitely at a dly. dose of 200 mg.
Coccidioimycosis: 200-400 mg x 1 /d for 11-24 months. For some infect. and meningeal dis., 800 mg/d may be used.
Invasive candidiasis: load. dose: 800 mg on 1st D, subseq. dose: 400 mg ×1/ d. In gral., the recomm. durat. of ther. for candidemia is for 2 weeks after first neg. blood cult. result and resolut. of signs and sympt. attributable to candidemia.
Tmt. of mucos. candidiasis: Oropharyng. candidiasis. Load. dose: 200 mg- 400 mg on 1st D, subseq. dose: 100 mg- 200 mg ×1/d, for 7 to 21 d. (until oropharyng. candid. is in remiss.). Longer periods may be used in pts. with sev. comprom. immune funct.
Esophag. candid. : Loading dose: 200 mg- 400 mg on 1st d, subseq. dose: 100 mg- 200 mg×1/d, 14- 30 days (until oesophag. candid. is in remiss.). Longer periods may be used in pts. with sev. comprom. immune funct.
Candiduria : 200 mg to 400 mg ×1/d, for 7– 21 d. Longer periods may be used in pts. with sev. comprom. immune funct.
Chron. atrophic candidiasis : 50 mg ×1/d, 14 d.
Chronic mucocutan. candidiasis: 50 mg- 100 mg ×1/d, up to 28 d. Longer periods depend. on both the sever. of infect. or underl. immune comprom. and infect.
Prevent. of relapse of mucosal candid. in pts. infect. with HIV who are at high risk of relapse : Oropharynge. candid. : 100 mg- 200 mg /d or 200 mg 3 times per wk., an indef. period for ptts. with chron. immune suppress.
Oesophag. candidias. : 100 mg- 200 mg ×1/d or 200 mg 3 times per wk. , an indef. period for pts. with chron. immune suppress.
Prophylax. of candidal infect. : 200 mg -400 mg ×1/d, tmt. should start several days before anticipated onset of neutropenia and cont. for 7 d after recovery from neutropenia after the neutrophil count rises above 1000 cells per mm3.
Chldr. of all ages: A max. dose of 400 mg/d should not be exceeded in paed. pop See prescr. info. for full details.
Tmt. of: Cryptococcal meningitis . Coccidioidomycosis . Invas. candidiasis. Mucosal candidiasis (includ. oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chron. mucocutaneous candidiasis). Chron. oral atrophic candidiasis (denture sore mouth) if dental hygiene topical tmt. are insuffic.
Indic. in adult. for the prophylax. of: Relapse of cryptococcal meningit. in pts. with high risk of recurr. Relapse of oropharyngeal or oesophageal candidiasis in pts. infect. with HIV who are at high risk of relapse. Prophylax. of candidal infect. in
pts. with prolong. neutropen. (such as pts. with haematolog. malignanc. receiv. chemother. or pts. receiv. Haematopoet. Stem Cell Transplant).
Indic. in term newborn infants, infants, toddlers, child. and adolesc. aged from 0- 17 yrs. old for: Tmt. of mucos. candidias. (oropharyng.,, oesophageal), invas. candidias., cryptococcal meningit. and prophylax. of candidal infect. in immunocomprom. pts.
Fluconazole can be used as mainten. ther. to prevent relapse of cryptococcal meningit. in child. with high risk of reoccurr.
Ther. may be instituted before the result of the cult. and other lab. studies are known; however, once these reults available, anti-infect. ther. should be adjust. accord. Consider. should be given to offic. guidance on the appropr. use of antifung.
C/I: Hypersens. There is no info. reg. cross hypersens. between fluconazole and other azoles. Caution should be used in prescr. fluconazol to ptt. with hypersens. to other azoles. Coadministr. of other drugs known to prolong the QT interval and which are metabol. via the enzyme CYP3A4 such as erythromycin, pimozide and quinidine are contraindic.
